Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 215

The DOI matches its Crossref record.

Long-term Efficacy of Vedolizumab for Crohn’s Disease

Open access
Vermeire, Severine, Loftus, Edward V., Colombel, Jean-Frédéric, Feagan, Brian G., Sandborn, William J., Sands, Bruce E., Danese, Silvio, D’Haens, Geert R., Kaser, Arthur, Panaccione, Remo, Rubin, David T., Shafran, Ira, McAuliffe, Megan, Kaviya, Arpeat, Sankoh, Serap, Mody, Reema, Abhyankar, Brihad, Smyth, Michael · 2016 · Journal of Crohn's and Colitis

Abstract

BACKGROUND AND AIMS: Vedolizumab is a gut-selective α4β7 integrin antagonist therapy for ulcerative colitis and Crohn's disease. The GEMINI long-term safety [LTS] trial is an ongoing open-label study investigating the safety of vedolizumab. We present interim exploratory analyses of efficacy in patients with Crohn's disease. METHODS: Patients from the C13004, GEMINI 2 and GEMINI 3 studies and vedolizumab-naïve patients could enrol in GEMINI LTS and received vedolizumab every 4 weeks. Data were collected from May 22, 2009 to June 27, 2013. Outcomes of clinical response and remission, defined by the Harvey-Bradshaw Index, and health-related quality of life [HRQL] were assessed for up to 152 weeks of treatment in the efficacy population. RESULTS: Among patients with response at week 6 in GEMINI 2 who received vedolizumab continuously, 83% [n=100/120] and 89% [n=62/70] of patients with available data were in remission after 104 and 152 weeks, respectively. Increased dosing frequency from every 8 weeks [GEMINI 2] to every 4 weeks [GEMINI LTS] improved outcomes in patients who had withdrawn early from GEMINI 2, with 47% [n=27/57] experiencing clinical response and 32% [n=18/57] in remission at week 52 of GEMINI LTS [up from 39% and 4% before the dose increase]. Similar improvements were observed regardless of prior tumour necrosis factor [TNF] antagonist exposure. Long-term benefits of HRQL were also observed. CONCLUSIONS: The clinical benefits of vedolizumab continued with long-term treatment regardless of prior TNF antagonist exposure. Increased dosing frequency might improve outcomes in patients who lose response to conventional 8-weekly dosing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ecco-jcc/jjw176

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 215

Metadata

Authors
Vermeire, S., Loftus, E. V., Colombel, J.-F., Feagan, B. G., Sandborn, W. J., Sands, B. E., Danese, S., D’Haens, G. R., Kaser, A., Panaccione, R., Rubin, D. T., Shafran, I., McAuliffe, M., Kaviya, A., Sankoh, S., Mody, R., Abhyankar, B., & Smyth, M.
Venue
Journal of Crohn's and Colitis
Published
2016-09-28
Volume
11
Issue
4
Pages
jjw176
ISSN
  • 1873-9946 (ISSN-L)
  • 1876-4479
OpenAlex
W2523926044
Cited by
215
References
0
FWCI
23.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term Efficacy of Vedolizumab for Crohn’s Disease. https://app.cochat.ai/papers/10.1093/ecco-jcc/jjw176
The paper
Vermeire, S., Loftus, E. V., Colombel, J.-F., Feagan, B. G., Sandborn, W. J., Sands, B. E., Danese, S., D’Haens, G. R., Kaser, A., Panaccione, R., Rubin, D. T., Shafran, I., McAuliffe, M., Kaviya, A., Sankoh, S., Mody, R., Abhyankar, B., & Smyth, M. (2016). Long-term Efficacy of Vedolizumab for Crohn’s Disease. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjw176

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.